Whitehawk Gets a Buy From Stifel as Analysts Bet on a More Stable Cancer Drug
Three ADC trials and cash into 2028 are the setup.
Three ADC trials and cash into 2028 are the setup.
Tempus AI and Whitehawk Therapeutics announce multi-year collaboration using AI and real-world data to develop targeted antibody drug conjugate therapies for cancer patients.